Science & Medicine

Pipeline

  • Name
  • Indication
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approved
BylvayTM (odevixibat)
PFIC
Description

Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi). Albireo is developing Bylvay to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis, biliary atresia and Alagille syndrome.

Alagille Syndrome
Description

Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi). Albireo is developing Bylvay to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis, biliary atresia and Alagille syndrome.

Biliary Atresia
Description

Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi). Albireo is developing Bylvay to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis, biliary atresia and Alagille syndrome.

Other Cholestatic

A3907
Adult Liver Diseases
Description

A3907 is an oral systemic apical sodium-dependent bile acid transporter (ASBT) inhibitor being developed for adult cholestatic liver diseases such as primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).


A2342
Viral Cholestatic Disease
Description

A2342 is an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor for viral disease and cholestatic diseases, which is moving ahead with IND-enabling studies.


Bile Acid Modulators
Undisclosed

Elobixibat
Chronic Constipation
Description

Elobixibat is an IBATi approved in Japan and Thailand for the treatment of chronic constipation, the first IBAT inhibitor to be approved anywhere in the world.


Bylvay™ (odevixibat) is approved for the treatment of pruritus in PFIC in the U.S. and for PFIC in Europe. Elobixibat is approved for chronic constipation in Japan and Thailand. All other drugs and indications are currently investigational.

Clinical Trials

Albireo is currently working on several clinical trials. Learn more about the trials we currently have in progress.

LEARN MORE